

Alessandro Pratesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6966815/publications.pdf>

Version: 2024-02-01

62
papers

1,438
citations

257101

24
h-index

360668

35
g-index

63
all docs

63
docs citations

63
times ranked

1459
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2022, 226, 111657.	1.5	11
2	Protein-Based Delivery Systems for Anticancer Metallo drugs: Structure and Biological Activity of the Oxaliplatin/ β^2 -Lactoglobulin Adduct. <i>Pharmaceutics</i> , 2022, 15, 425.	1.7	5
3	Anti-Staphylococcal Activity of the Auranofin Analogue Bearing Acetylcysteine in Place of the Thiosugar: An Experimental and Theoretical Investigation. <i>Molecules</i> , 2022, 27, 2578.	1.7	6
4	Computationally enhanced X-ray diffraction analysis of a gold(III) complex interacting with the human telomeric DNA G-quadruplex. Unravelling non-unique ligand positioning. <i>International Journal of Biological Macromolecules</i> , 2022, 211, 506-513.	3.6	1
5	When ferrocene and diiron organometallics meet: triiron vinyliminium complexes exhibit strong cytotoxicity and cancer cell selectivity. <i>Inorganic Chemistry Frontiers</i> , 2022, 9, 5118-5139.	3.0	9
6	Medicinal Hypervalent Tellurium Prodrugs Bearing Different Ligands: A Comparative Study of the Chemical Profiles of AS101 and Its Halido Replaced Analogues. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7505.	1.8	3
7	The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct. <i>Dalton Transactions</i> , 2021, 50, 68-71.	1.6	5
8	Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 39-46.	2.5	53
9	Two mixed valence diruthenium(II , III) isomeric complexes show different anticancer properties. <i>Dalton Transactions</i> , 2021, 50, 9643-9647.	1.6	28
10	Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1874.	1.8	7
11	Editorial: The Golden Future in Medicinal Chemistry: Perspectives and Resources From Old and New Gold-Based Drug Candidates. <i>Frontiers in Chemistry</i> , 2021, 9, 665244.	1.8	4
12	Thermodynamic Evaluation of the Interactions between Anticancer Pt(II) Complexes and Model Proteins. <i>Molecules</i> , 2021, 26, 2376.	1.7	7
13	Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA-PEG nanoparticles. <i>BioMetals</i> , 2021, 34, 867-879.	1.8	13
14	A focus on the biological targets for coinage metal-NHCs as potential anticancer complexes. <i>Journal of Inorganic Biochemistry</i> , 2021, 217, 111355.	1.5	29
15	Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study. <i>Inorganica Chimica Acta</i> , 2021, 520, 120297.	1.2	12
16	Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments. <i>Biomedicines</i> , 2021, 9, 504.	1.4	35
17	Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds. <i>Coordination Chemistry Reviews</i> , 2021, 438, 213905.	9.5	23
18	Anticancer Diiron Vinyliminium Complexes: A Structure-Activity Relationship Study. <i>Pharmaceutics</i> , 2021, 13, 1158.	2.0	18

#	ARTICLE	IF	CITATIONS
19	Iron Binding in the Ferroxidase Site of Human Mitochondrial Ferritin. <i>Chemistry - A European Journal</i> , 2021, 27, 14690-14701.	1.7	2
20	Direct detection of iron clusters in L ferritins through ESI-MS experiments. <i>Dalton Transactions</i> , 2021, 50, 16464-16467.	1.6	6
21	Role of the (pseudo)halido ligand in ruthenium(II)- <i>p</i> -cymene λ^2 -amino acid complexes in speciation, protein reactivity and cytotoxicity. <i>Dalton Transactions</i> , 2021, 50, 15760-15777.	1.6	5
22	Synthesis, DNA binding studies, and antiproliferative activity of novel Pt(II)-complexes with an L-alanyl-based ligand. <i>Journal of Inorganic Biochemistry</i> , 2020, 203, 110868.	1.5	11
23	On the Different Mode of Action of Au(I)/Ag(I)-NHC Bis-Anthracenyl Complexes Towards Selected Target Biomolecules. <i>Molecules</i> , 2020, 25, 5446.	1.7	11
24	Reactions of Medicinal Gold(III) Compounds With Proteins and Peptides Explored by Electrospray Ionization Mass Spectrometry and Complementary Biophysical Methods. <i>Frontiers in Chemistry</i> , 2020, 8, 581648.	1.8	43
25	Native mass spectrometry of human carbonic anhydrase I and its inhibitor complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2020, 25, 979-993.	1.1	5
26	Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PET3)I: A Theoretical and Experimental Study. <i>Frontiers in Chemistry</i> , 2020, 8, 812.	1.8	31
27	A mixed-valence diruthenium(II,III) complex endowed with high stability: from experimental evidence to theoretical interpretation. <i>Dalton Transactions</i> , 2020, 49, 14520-14527.	1.6	25
28	Alkyne Functionalization of a Photoactivated Ruthenium Polypyridyl Complex for Click-Enabled Serum Albumin Interaction Studies. <i>Inorganic Chemistry</i> , 2020, 59, 7710-7720.	1.9	14
29	ESI MS studies highlight the selective interaction of Auranofin with protein free thiols. <i>Dalton Transactions</i> , 2020, 49, 5906-5913.	1.6	57
30	Protein interactions of dirhodium tetraacetate: a structural study. <i>Dalton Transactions</i> , 2020, 49, 2412-2416.	1.6	29
31	The cisplatin/serum albumin system: A reappraisal. <i>Inorganica Chimica Acta</i> , 2019, 495, 118983.	1.2	26
32	Structural Characterization of a Gold/Serum Albumin Complex. <i>Inorganic Chemistry</i> , 2019, 58, 10616-10619.	1.9	34
33	Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin. <i>BioMetals</i> , 2019, 32, 939-948.	1.8	12
34	The leading established metal-based drugs: a revisit of their relevant physico-chemical data. <i>BioMetals</i> , 2019, 32, 813-817.	1.8	17
35	Photocytotoxic Pt(IV) complexes as prospective anticancer agents. <i>Dalton Transactions</i> , 2019, 48, 10933-10944.	1.6	28
36	Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 656-660.	1.3	64

#	ARTICLE	IF	CITATIONS
37	A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies. <i>ChemMedChem</i> , 2018, 14, 182-188.	1.6	35
38	The NAMI A " human ferritin system: a biophysical characterization. <i>Dalton Transactions</i> , 2018, 47, 11429-11437.	1.6	24
39	Reactions of Auranofin and Its Pseudohalide Derivatives with Serum Albumin Investigated through ESI-Q-TOF MS. <i>Inorganic Chemistry</i> , 2018, 57, 10507-10510.	1.9	43
40	Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation. <i>Inorganica Chimica Acta</i> , 2018, 470, 318-324.	1.2	8
41	Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study. <i>Oncotarget</i> , 2018, 9, 28042-28068.	0.8	53
42	Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments. <i>Talanta</i> , 2017, 167, 30-38.	2.9	30
43	Synthesis of dicarba-cyclooctapeptide Somatostatin analogs by conventional and MW-assisted RCM: A study about the impact of the configuration at C \pm of selected amino acids. <i>Chemical Engineering and Processing: Process Intensification</i> , 2017, 122, 365-372.	1.8	4
44	Ruthenium arene complexes with triphenylphosphane ligands: cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution. <i>New Journal of Chemistry</i> , 2017, 41, 14574-14588.	1.4	37
45	Auranofin, Et ₃ PAuCl, and Et ₃ PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 997-1001.	1.3	91
46	ESI-MS studies of the reactions of novel platinum(II) complexes containing O,O ² -chelated acetylacetonate and sulfur ligands with selected model proteins. <i>BioMetals</i> , 2017, 30, 609-614.	1.8	12
47	DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst _{2,5} Receptors. <i>Frontiers in Chemistry</i> , 2017, 5, 8.	1.8	4
48	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. <i>Oncotarget</i> , 2017, 8, 96062-96078.	0.8	42
49	Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2016, 163, 318-322.	1.5	5
50	Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 1-6.	1.5	26
51	New gold carbene complexes as candidate anticancer agents. <i>BioMetals</i> , 2016, 29, 905-911.	1.8	29
52	New Pyrimido-Indole Compound CD-160130 Preferentially Inhibits the K _v 11.1B Isoform and Produces Antileukemic Effects without Cardiotoxicity. <i>Molecular Pharmacology</i> , 2015, 87, 183-196.	1.0	26
53	Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 3988-4001.	1.5	7
54	Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation. <i>Journal of Inorganic Biochemistry</i> , 2014, 136, 161-169.	1.5	88

#	ARTICLE	IF	CITATIONS
55	{Ru(CO) _x }-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. <i>Polyhedron</i> , 2014, 81, 227-237.	1.0	24
56	Dioxygen Oxidation Cu(II) → Cu(III) in the Copper Complex of <i>cyclo</i> (Lys- <i>d</i> -His- ² Ala-His): A Case Study by EXAFS and XANES Approach. <i>Inorganic Chemistry</i> , 2012, 51, 7969-7976.	1.9	14
57	Biotin Derivatives Carrying Two Chelating DOTA Units. Synthesis, in Vitro Evaluation of Biotinidases Resistance, Avidin Binding, and Radiolabeling Tests. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 432-440.	2.9	9
58	Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. <i>Chemical Communications</i> , 2010, 46, 7001.	2.2	64
59	Short-chain oligopeptides with copper(II) binding properties: The impact of specific structural modifications on the copper(II) coordination abilities. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 678-688.	1.5	18
60	Impact of ring size on the copper(II) coordination abilities of cyclic tetrapeptides. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 813-817.	1.5	26
61	New Copper(II)/Cyclic Tetrapeptide System That Easily Oxidizes to Copper(III) under Atmospheric Oxygen. <i>Inorganic Chemistry</i> , 2007, 46, 10038-10040.	1.9	29
62	Ferritin-based anticancer metallodrug delivery: Encapsulation of Arsenoplatin-1 within the ferritin nanocage. , 0, , .		0